AMPE - Ampio Pharma updates on phase I trial enrolment for COVID-19 ampion study

Biopharmaceutical company Ampio Pharmaceuticals (AMPE) announces that its ongoing U.S. Phase I clinical trial for inhalation treatment of COVID-19 with Ampion (AP-014) is 55% enrolled.Inhaled Ampion specifically targets inflammation in the lung and is currently being investigated to determine whether its use will improve the clinical outcome for patients with respiratory distress due to COVID-19.The study of inhaled Ampion in COVID-19 patients has exhibited no drug-related serious adverse events, the company said.In addition to the U.S. based trial of inhaled Ampion, the company has also started a global study commencing in Israel and the U.S. for patients with moderate to severe COVID-19, the company had said earlier this month.

For further details see:

Ampio Pharma updates on phase I trial enrolment for COVID-19 ampion study